Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of GLPG0974 in mild to moderate ulcerative colitis
2012-005521-73Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing GLPG0974 with Placebo (2 arms). Primary endpoint: Safety and tolerability of GLPG0974 over 28 days. Started Feb 2013; status: completed.
02
Drugs
GLPG0974
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2012-005521-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005521-73.